What is the CPH.TO share price today?

This page shows the latest available Cipher Pharmaceuticals Inc. (CPH.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is Cipher Pharmaceuticals Inc. listed?

Cipher Pharmaceuticals Inc. trades on the Toronto Stock Exchange under the symbol CPH.TO, ISIN CA17253X1050.

How large is Cipher Pharmaceuticals Inc.?

Its market capitalisation is approximately 363.1M CAD, based on the latest available price and share count from our data provider.

Toronto Stock Exchange (TSX) · CPH.TO · ISIN CA17253X1050

Cipher Pharmaceuticals Inc.

14.67 CAD

−0.19(−1.28%)

Previous close · Sep 18, 16:00 ET

Data last updated: Sep 18, 16:00 ET (18 h ago)· Delayed exchange data

Cipher Pharmaceuticals Inc. (CPH.TO) trades on the Toronto Stock Exchange and operates in the Drug Manufacturers - Specialty & Generic industry. Its market capitalisation is approximately 363.1M CAD. The company reports around 5 employees. Its ISIN is CA17253X1050. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Checking today's session…

Key facts

Exchange

Toronto Stock Exchange (TSX)

ISIN

CA17253X1050

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

Market cap

372.49M CAD

Employees

Previous close

14.86 CAD

Day range

14.46 – 14.81

52-week range

12.48 – 20.56

Volume

34.32K

50-day average

15.44 CAD

200-day average

16.00 CAD

Asset type

Equity

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.

Company website

Frequently asked

What is the CPH.TO share price today?: This page shows the latest available Cipher Pharmaceuticals Inc. (CPH.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is Cipher Pharmaceuticals Inc. listed?: Cipher Pharmaceuticals Inc. trades on the Toronto Stock Exchange under the symbol CPH.TO, ISIN CA17253X1050.
How large is Cipher Pharmaceuticals Inc.?: Its market capitalisation is approximately 363.1M CAD, based on the latest available price and share count from our data provider.

All Cipher Pharmaceuticals Inc. data comes from exchange and provider feeds for the Toronto Stock Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.